Format

Send to

Choose Destination
Ocul Immunol Inflamm. 2016;24(1):96-8. doi: 10.3109/09273948.2014.999377. Epub 2015 Mar 11.

Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis.

Author information

1
a ÓMMA Eye Center , Zurich , Switzerland and.
2
b University of Zurich , Zurich , Switzerland.

Abstract

BACKGROUND:

Rituximab is a widely used biologic agent, which has shown favourable results in the treatment of vasculitis. But immunosuppressive treatment also bears the risk of severe complications.

METHODS:

A patient with rheumatoid arthritis, progressive scleromalacia, and acute retinal necrosis on therapy with rituximab is reported.

RESULTS:

For the first time, a correlation between rituximab and acute retinal necrosis in a patient with progressive rheumatoid scleromalacia is shown.

CONCLUSIONS:

Although rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of acute retinal necrosis.

KEYWORDS:

Acute retinal necrosis; herpes simplex virus; necrotizing scleritis; ocular inflammation; rituximab

PMID:
25760911
DOI:
10.3109/09273948.2014.999377
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center